|
|
|
|
| LEADER |
00000cam a2200000xa 4500 |
| 001 |
b12935446 |
| 003 |
CoU |
| 005 |
20230505053432.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
210213s2021 gw o 000 0 eng d |
| 019 |
|
|
|a 1240719628
|
| 020 |
|
|
|a 9783527826872
|q (electronic bk. ;
|q oBook)
|
| 020 |
|
|
|a 3527826874
|q (electronic bk. ;
|q oBook)
|
| 020 |
|
|
|a 9783527826858
|
| 020 |
|
|
|a 3527826858
|
| 020 |
|
|
|a 3527826866
|
| 020 |
|
|
|a 9783527826865
|q (electronic bk.)
|
| 020 |
|
|
|z 9783527347544
|q (hbk.)
|
| 024 |
7 |
|
|a 10.1002/9783527826872
|
| 035 |
|
|
|a (OCoLC)wol1237407353
|
| 035 |
|
|
|a (OCoLC)1237407353
|z (OCoLC)1240719628
|
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d UIU
|d OCLCO
|d DG1
|d UKMGB
|d UKAHL
|d OCLCF
|d N$T
|d SOE
|d OCLCQ
|d OCLCO
|d SFB
|d OCLCQ
|d UPM
|d OCLCQ
|
| 049 |
|
|
|a GWRE
|
| 050 |
|
4 |
|a RM301.25
|
| 245 |
0 |
0 |
|a Successful drug discovery.
|n Volume 5
|h [electronic resource] /
|c edited by Janos Fischer, Christian Klein, Wayne E. Childers.
|
| 260 |
|
|
|a Weinheim :
|b Wiley-VCH,
|c 2021.
|
| 300 |
|
|
|a 1 online resource (317 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 505 |
0 |
|
|a Cover -- Title Page -- Copyright -- Contents -- Advisory Board Members -- Preface -- Part I General Aspects -- Chapter 1 Drug Discovery in Academia -- 1.1 Introduction -- 1.2 Repurposing Drugs -- 1.2.1 Thalidomide Derivatives -- 1.2.2 Chemotherapy: Nitrogen Mustards -- 1.3 Pregabalin -- 1.4 Natural Product-Derived Drug Discovery -- 1.4.1 Antibiotics -- 1.4.2 Anticancer Drugs -- 1.4.2.1 Camptothecin -- 1.4.2.2 Taxol -- 1.4.2.3 Epothilones -- 1.4.2.4 Eribulin -- 1.4.3 Artemisinin and Artemether -- 1.4.4 Carfilzomib -- 1.5 Biologic Drugs -- 1.5.1 Insulin -- 1.5.2 Rituximab -- 1.5.3 Alglucerase.
|
| 505 |
8 |
|
|a 1.6 Conceptionally New Small Molecule Drugs -- 1.6.1 Histone Deacetylase Inhibitors -- 1.6.2 Acyclic Nucleoside Phosphonates -- 1.6.3 Darunavir -- 1.6.4 Sunitinib -- 1.7 Sweet Spot for Academic Drug Discovery -- List of Abbreviations -- References -- Biography -- Chapter 2 From Degraders to Molecular Glues: New Ways of Breaking Down Disease-Associated Proteins -- 2.1 Introduction -- 2.2 Definition and Historical Development of Degraders -- 2.3 The Ubiquitin-Proteasome System and Considerations of E3 Ligases -- 2.4 General Design Aspects.
|
| 505 |
8 |
|
|a 2.5 Differentiation of the Degrader Technology to Traditional Approaches -- 2.5.1 The Ability to Expand the Druggable Proteome -- 2.5.2 Overcoming the Accumulation of Target Protein -- 2.5.3 Abrogating Scaffolding Functions -- 2.5.4 Creating Target Specificity -- 2.5.5 Catalytic Mode of Action -- 2.5.6 Event-Driven Pharmacology and Prolonged PD Effect -- 2.6 Potential Disadvantages and Limitations of Degraders -- 2.7 Molecular Glue-like Degraders and Monovalent Degraders -- 2.7.1 Definitions and Historical Perspective -- 2.7.2 State of the Art -- 2.8 Future Directions (Status Q3 2020)
|
| 505 |
8 |
|
|a 2.9 Summary and Conclusions -- Acknowledgments -- List of Abbreviations -- References -- Biographies -- Part II Drug Class Studies -- Chapter 3 GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity -- 3.1 Introduction -- 3.2 GLP-1 Biology -- 3.2.1 GLP-1 Receptor Binding and Activation -- 3.2.2 GLP-1 Pharmaceutical Developments -- 3.3 Ex4-Based Analogues -- 3.3.1 Exenatide -- 3.3.2 Exenatide LAR -- 3.3.3 Lixisenatide -- 3.3.4 Efpeglenatide -- 3.3.5 Pegylated Loxenatide -- 3.4 GLP-1 Based Analogues -- 3.4.1 Liraglutide -- 3.4.2 Semaglutide -- 3.4.3 Taspoglutide.
|
| 505 |
8 |
|
|a 3.4.4 Albiglutide and Albenatide -- 3.4.5 Dulaglutide -- 3.5 Co-agonists -- 3.5.1 GLP-1/GIP Co-agonists -- 3.5.2 GLP-1/Glucagon Co-agonists -- 3.5.2.1 Other GLP-1R Agonists -- 3.6 Summary -- List of Abbreviations -- References -- Biographies -- Chapter 4 Recent Advances on SGLT2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events -- 4.1 Introduction -- 4.2 The Mechanism of Action of SGLT2 Inhibitors -- 4.3 Synthetic Approaches to Gliflozins -- 4.3.1 Dapagliflozin -- 4.3.2 Sotagliflozin -- 4.3.3 Empagliflozin -- 4.3.4 Bexagliflozin -- 4.3.5 Luseogliflozin.
|
| 505 |
8 |
|
|a 4.3.6 Tofogliflozin.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Drug development
|x History
|y 21st century.
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670.
|
| 655 |
|
7 |
|a History.
|2 fast
|0 (OCoLC)fst01411628.
|
| 700 |
1 |
|
|a Fischer, János,
|e editor.
|0 http://id.loc.gov/authorities/names/nb2006004929
|1 http://isni.org/isni/0000000115896215.
|
| 700 |
1 |
|
|a Klein, Christian,
|e editor.
|0 http://id.loc.gov/authorities/names/n96040915.
|
| 700 |
1 |
|
|a Childers, Wayne E.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|z 9783527347544.
|
| 856 |
4 |
0 |
|u https://colorado.idm.oclc.org/login?url=https://onlinelibrary.wiley.com/doi/book/10.1002/9783527826872
|z Full Text (via Wiley)
|
| 907 |
|
|
|a .b129354466
|b 06-13-23
|c 05-12-23
|
| 998 |
|
|
|a web
|b 05-31-23
|c b
|d b
|e -
|f eng
|g gw
|h 0
|i 1
|
| 907 |
|
|
|a .b129354466
|b 06-01-23
|c 05-12-23
|
| 944 |
|
|
|a MARS - RDA ENRICHED
|
| 915 |
|
|
|a -
|
| 956 |
|
|
|a Wiley Online Library eBooks
|
| 956 |
|
|
|b Wiley Online Library: Complete oBooks
|
| 999 |
f |
f |
|i 60c368f7-ab0c-53ac-af37-b300d82e61e4
|s 036ca9a6-a3b6-544f-a9aa-8d4f62734628
|
| 952 |
f |
f |
|p Can circulate
|a University of Colorado Boulder
|b Online
|c Online
|d Online
|e RM301.25
|h Library of Congress classification
|i web
|n 1
|
